(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox.

GUEST:
Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.

<p>(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox.

GUEST:
Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.</p>

Scarlet Fu and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company research. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.

<p>Scarlet Fu and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company research. Watch us LIVE on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.</p>

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze markets, companies and industries.

Bloomberg Intelligence

Shire’s Ornskov on $1 Billion Potential for Dry-Eye Drug(Audio)

Shire's Ornskov on $1 Billion Potential for Dry-Eye Drug(Audio)

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/24242024-1c57-46f9-88fc-ae3c009ae004/transcript

Advertisement